Answer : The driving factors of the GLP-1 analogues market are the rising prevalence of diabetes and obesity, driving demand for effective treatment options
In this article, Ill unpack what CMS originally planned to do, what these GLP-1s are currently approved for, and how the reversal impacts patients, physicians, and the broader health system
According to the company's terms, services are currently available in certain states
Farr, O
I have worked closely with Jose Manuel for over 20 years, and I have every confidence that his talent, leadership and vision make him ideally suited to become CEO of Puig, Puig said in a statement
In the UK, retatrutide is only accessible through approved clinical trials